These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22505535)

  • 21. Introduction. Herceptin: HER2 status--changing clinical practice.
    Piccart M; Kaufmann M
    Eur J Cancer; 2001 Jan; 37 Suppl 1():S1-2. PubMed ID: 11167084
    [No Abstract]   [Full Text] [Related]  

  • 22. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
    Liao C; Yin F; Huang P; Cao Y; Gao F
    Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
    [No Abstract]   [Full Text] [Related]  

  • 23. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 24. Mechanisms of resistance to HER2 target therapy.
    Tortora G
    J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer: the upgraded role of HER-3 and HER-4.
    Karamouzis MV; Badra FA; Papavassiliou AG
    Int J Biochem Cell Biol; 2007; 39(5):851-6. PubMed ID: 17254832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 27. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ten remarkable years.
    Sledge GW
    Clin Breast Cancer; 2010 Jun; 10(3):178. PubMed ID: 20497915
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Her-2/neu in breast cancer: as easy as this!
    Azim H; Azim HA
    Oncology; 2008; 74(3-4):150-7. PubMed ID: 18708732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 32. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
    Garnock-Jones KP; Keating GM; Scott LJ
    BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285
    [No Abstract]   [Full Text] [Related]  

  • 33. HER2011: the changing face of HER2-positive breast cancer.
    Sledge GW
    Clin Breast Cancer; 2011 Mar; 11(1):9. PubMed ID: 21421515
    [No Abstract]   [Full Text] [Related]  

  • 34. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):4. PubMed ID: 19364050
    [No Abstract]   [Full Text] [Related]  

  • 35. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
    Cho WC; Roukos DH
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
    [No Abstract]   [Full Text] [Related]  

  • 36. [Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].
    Bershteĭn LM
    Vopr Onkol; 2013; 59(3):292-8. PubMed ID: 23909028
    [No Abstract]   [Full Text] [Related]  

  • 37. Neratinib (HKI-272) in the treatment of breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M
    Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.
    Kurosumi M
    Breast Cancer; 2009; 16(4):283. PubMed ID: 19756922
    [No Abstract]   [Full Text] [Related]  

  • 39. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
    Viani GA; Afonso SL; Stefano EJ; De Fendi LI; Soares FV
    BMC Cancer; 2007 Aug; 7():153. PubMed ID: 17686164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
    Sardesai SD; Storniolo AM
    Womens Health (Lond); 2015 Jun; 11(3):281-94. PubMed ID: 26102468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.